Natco Pharma Limited Stock Price Today (NSE: NATCOPHARM)
Fundamental Score
Natco Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Natco Pharma Limited share price today is ₹813.30, down 0.71% on NSE/BSE as of 16 September 2026. Natco Pharma Limited (NATCOPHARM) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹14.56K (Cr). The 52-week high for NATCOPHARM share price is ₹1226.80 and the 52-week low is ₹789.00. At a P/E ratio of 12.73x, NATCOPHARM is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 16.86% and a debt-to-equity ratio of 0.08.
Natco Pharma Limited Share Price Chart — NSE/BSE Historical Performance
Natco Pharma Limited share price chart: -9.31% return over the past month. 52-week high ₹1226.80, 52-week low ₹789.00.
Natco Pharma Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹813.10 | ₹828.75 | ₹801.00 | ₹813.30 | 4.93L (Cr) | |
| ₹816.95 | ₹831.45 | ₹812.30 | ₹819.15 | 4.35L (Cr) | |
| ₹816.10 | ₹821.45 | ₹801.40 | ₹815.35 | 5.68L (Cr) | |
| ₹825.55 | ₹832.15 | ₹816.00 | ₹818.65 | 2.36L (Cr) | |
| ₹827.90 | ₹838.90 | ₹815.20 | ₹826.30 | 5.37L (Cr) | |
| ₹838.30 | ₹846.85 | ₹823.40 | ₹825.75 | 3.03L (Cr) | |
| ₹829.00 | ₹841.50 | ₹828.00 | ₹838.30 | 3.01L (Cr) | |
| ₹839.00 | ₹841.80 | ₹826.50 | ₹828.65 | 4.45L (Cr) | |
| ₹843.30 | ₹849.95 | ₹835.80 | ₹838.30 | 2.18L (Cr) | |
| ₹848.00 | ₹857.35 | ₹833.50 | ₹843.25 | 4.73L (Cr) |
Natco Pharma Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹841.50 | ₹857.35 | ₹801.00 | ₹813.30 | -3.35% | |
| ₹921.00 | ₹964.85 | ₹835.50 | ₹841.50 | -8.63% | |
| ₹939.80 | ₹997.30 | ₹911.60 | ₹917.00 | -2.43% | |
| ₹1010.00 | ₹1014.00 | ₹839.00 | ₹931.30 | -7.79% | |
| ₹1098.90 | ₹1226.80 | ₹1000.00 | ₹1015.90 | -7.55% | |
| ₹998.60 | ₹1134.85 | ₹978.45 | ₹1095.75 | +9.73% | |
| ₹925.15 | ₹1053.00 | ₹924.40 | ₹974.20 | +5.30% | |
| ₹823.90 | ₹999.00 | ₹810.55 | ₹988.50 | +19.98% | |
| ₹901.05 | ₹960.40 | ₹806.05 | ₹835.90 | -7.23% | |
| ₹885.15 | ₹950.90 | ₹864.30 | ₹903.05 | +2.02% | |
| ₹819.90 | ₹938.15 | ₹792.05 | ₹877.25 | +6.99% | |
| ₹799.90 | ₹864.80 | ₹796.75 | ₹819.90 | +2.50% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Natco Pharma Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Natco Pharma Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NATCOPHARM across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (16.86%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (17.89%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (37.80%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 12.73 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (14.72% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (26.76% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (26.33% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.08)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (41.62x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 5.59)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹3865.40 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Profit Decline Concern (-57.04%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-44.68%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Natco Pharma Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Natco Pharma Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Natco Pharma LimitedNatco Pharma Li...Selected✓ NATCOPHARM • 524816 | 64.8/100 | ₹813.30₹813 | ₹14558.07₹14558.07 | 12.73Average 12.7 Average | 16.86%Good 16.86% Good | 17.89%Good 17.89% Good | 0.08Excellent 0.1 Excellent | 26.33%Excellent 26.33% Excellent | 14.72%Good 14.72% Good | 0.62% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Natco Pharma Limited PE Ratio History
Historical price-to-earnings ratio for NATCOPHARM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹105.26 | ₹903.05 | 8.6x |
| FY 2024 | ₹77.34 | ₹1387.30 | 17.9x |
| FY 2023 | ₹39.18 | ₹811.35 | 20.7x |
| FY 2022 | ₹9.32 | ₹561.65 | 60.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Natco Pharma Limited Dividend History
Annual cash dividends paid by NATCOPHARM — dividend yield 0.62%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹107.80 Cr |
| FY 2024 | ₹170.80 Cr |
| FY 2023 | ₹100.40 Cr |
| FY 2022 | ₹82.20 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Natco Pharma Limited Quarterly Performance
Latest quarterly metrics for NATCOPHARM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-44.68%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-57.04%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
14.72%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
26.33%
Compounded annual net profit growth over 5 years
Natco Pharma Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for NATCOPHARM — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Natco Pharma Limited Financial Statements
Annual income statement, balance sheet and cash flow for Natco Pharma Limited (NATCOPHARM) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Natco Pharma Limited
About NATCOPHARM (Natco Pharma Limited)
Natco Pharma Ltd is a vertically integrated pharmaceutical powerhouse, carving a niche for itself in the complex world of oncology and specialty medicines. They are not merely manu...facturers; they are innovators, meticulously crafting finished dosage formulations and active pharmaceutical ingredients (APIs) with a focus on cutting-edge research and development. Their commitment extends beyond national borders, establishing a significant presence in both domestic and international markets. This dedication to research, coupled with strategic manufacturing capabilities, allows Natco Pharma to address unmet medical needs with accessible and high-quality pharmaceuticals, particularly in areas where treatment options are limited or prohibitively expensive. They stand as a testament to the power of scientific rigor and ethical business practices within the pharmaceutical landscape. The company's strategic vision encompasses a diverse therapeutic portfolio, reflecting a deep understanding of global healthcare needs. While oncology remains a cornerstone of their operations, Natco Pharma is also actively involved in developing solutions for other critical disease areas. This includes, but is not limited to, treatments for cardiovascular ailments, neurological disorders, and various autoimmune conditions. The breadth of their product pipeline underscores their commitment to addressing a wide range of patient needs, from chronic conditions to life-threatening illnesses. This multifaceted approach enables Natco Pharma to contribute meaningfully to improving patient outcomes worldwide. Beyond their immediate product offerings, Natco Pharma embodies a forward-thinking approach to healthcare. They are actively investing in the development of novel drug delivery systems and exploring biosimilar opportunities to expand access to affordable, life-saving medications. Their dedication to innovation extends beyond the laboratory, encompassing a commitment to ethical sourcing and responsible manufacturing practices. This holistic approach, combined with a strong focus on patient well-being, positions Natco Pharma as a responsible and impactful contributor to the global pharmaceutical industry, poised to shape the future of healthcare.
Company Details
Key Leadership
NATCOPHARM Share Price: Frequently Asked Questions
What is the current share price of Natco Pharma Limited?
Natco Pharma Limited (NATCOPHARM) trades at ₹813.30 on NSE and BSE. Market cap ₹14.56K (Cr). Educational data only.
What is the P/E ratio of Natco Pharma Limited?
Natco Pharma Limited has a P/E of 12.73x vs industry average 34.89x.
What is the Bull Run score for Natco Pharma Limited?
Natco Pharma Limited has a Bull Run score of 64.8/100 based on 25+ financial parameters.
Does Natco Pharma Limited pay dividends?
Natco Pharma Limited has a dividend yield of 0.62%. Past dividends don't guarantee future payments.
What is the ROE of Natco Pharma Limited?
Natco Pharma Limited has ROE of 16.86%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Natco Pharma Limited?
Natco Pharma Limited has debt-to-equity of 0.08.
Is Natco Pharma Limited a good investment?
Bull Run gives Natco Pharma Limited a score of 64.8/100. This is not investment advice — consult a SEBI-registered advisor.